PROGNOSTIC FACTORS IN CHRONIC MYELOMONOCYTIC LEUKEMIA FROM SOUTH AMERICA

BESTACH Y; CRISP R; VELLOSO E; GONZALEZ J; RIVAS MM; LIMA W; BELLI C; ARBELBIDE J; BASQUIERA A; LARRIPA I

Copenhague

Congreso; 21st Congress of European Hematology Association; 2016

European Hematology Association

Aims: To evaluate different prognostic factors for survival and evolution to AML, to validate the CPSS and to test thenew proposed cut-point for BM blast in South American population with CMML de novo.Methods: This is a multicenter analysis of 234 patients with de novo CMML from Argentina (152) and Brazil (82)diagnosed between March 1985 to December 2015. Clinical and hematologic data of patients was retrospectivelycollected and diagnosis of de novo CMML wasperformed according to WHO 2008 criteria.Results: The CMML population showed a median age of 71 (range 15-95) years being 83% older than 60 years old, witha sex ratio M/F: 2.1. With a median overall survival of 31 months, 56 (24%) evolved to AML and 122 (52%) died. Table 1shows the distribution of patients according to CMML-MD and CMML-MP subtypes; to WHO classification and to Germanproposal, karyotypes according to CPSS. Also, the different variants for the CPSS were calculated, including transfusionrequirement, hemoglobin level limit of 10g/dL and the adjusted by gender. As it is shown, most of the prognosticparameters and all CPSS proposals were useful to predict outcome in our population (Kaplan Meier and log-rank,p